Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Danaher Corporation › Chair reported a gift or transfer of 22K DHR shares Insider trades
Why it stands out Gift or transfer — classified separately from trades.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Nov 25, 2025
Reporting period Not applicable
Filed with the SEC Nov 25, 2025 Chair Indirect holding Gift / transfer
Context Classification gift transfer
Code G — gift, bequest or transfer
Planned / mechanical clue None found in footnotes
Only flagged when a footnote says so; never inferred
0001193125-25-297318
Filed / recorded Nov 25, 2025, 9:30 PM UTC
Added to OQRO Oct 2, 2026, 12:27 PM UTC
Data quality Verified: identifiers matched exactly
Reporting person Mitchell P Rales
Relationship Director, Officer
Officer title Chairman of Exec. Committee
Security Common Stock, par value $.01
Table Non-derivative (Table I)
Transaction date Nov 25, 2025
Acquired / disposed Disposed (D)
Shares owned after 890,625
Ownership form Indirect — Through the Mitchell P. Rales Family Trust
Footnotes from the filing The Reporting Person is the trustee of the Mitchell P. Rales Family Trust.
Around the same time Fund moves
96 tracked managers disclosed the same change for Q3 2025. From a 13F filed Dec 18, 2025 covering holdings at Sep 30, 2025 — a quarter-end snapshot, not a live trade.
Congress
Traded Nov 13, 2025 · disclosed 28 days later Joint
3 different filers disclosed DHR within 90 days.
Insider selling
Traded Nov 25, 2025 · filed 1 day later Not reported under a pre-arranged trading plan
Danaher's Chairman of Exec. Committee sold $8.27M of Danaher shares. The filing does not indicate a pre-arranged trading plan.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Apr 28, 2025 Congress Disclosed purchase of DHR — reported range $1,001 - $15,000 Sep 3, 2025 Congress Disclosed purchase of DHR — reported range $1,001 - $15,000 Sep 25, 2025 Congress Disclosed sale of DHR — reported range $1,001 - $15,000 Oct 7, 2025 Congress Disclosed purchase of DHR — reported range $1,001 - $15,000 Oct 21, 2025 Company filing · Form 8-K · Results Reported its results Oct 31, 2025 Insider · 1 person Insiders: 3 sales (~$129.6M) Nov 6, 2025 Company filing · Form 8-K · Executive change Changed a top executive or board member “On November 6, 2025, John T. Schwieters notified Danaher’s Board of Directors (“Board”) that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting.” Nov 10, 2025 FDA Recall: COULTER DxH Diluent, REF 628017 COULTER DxH ECO Diluent REF C67250 For use as an isotonic buffered diluent in conjunction with a cyanide-free lytic agent for c… Nov 10, 2025 Insider · 1 person Insiders: 2 sales (~$1.1M) Nov 11, 2025 Insider CFO sold ~$3.47M of DHR shares in the open market Nov 12, 2025 Insider · 2 people Insiders: 6 sales (~$100.3M) Nov 13, 2025 Congress Disclosed partial sale of DHR — reported range $1,001 - $15,000 Nov 17, 2025 FDA FDA device clearance: Access Rubella IgG Nov 18, 2025 Insider Director sold ~$747K of DHR shares in the open market Nov 25, 2025 Insider · 1 person Insiders: 2 sales (~$9.4M) What came next Nov 26, 2025 FDA Recall: Beckman Coulter UniCel Dxl 600, Part numbers: A71460, A71461, A30260; Immunoassay Method, Troponin Subunit Nov 26, 2025 FDA Recall: Beckman Coulter UniCel Dxl 800, Part numbers: 973100, A71456, A71457, A25288; Immunoassay Method, Troponin Subunit Dec 8, 2025 FDA Recall: The LDL-Cholesterol assay is comprised of two distinct phases. In phase one a unique detergent solubilizes cholesterol from non-LDL- lipoprotein particles. Thi… Dec 18, 2025